Deutsche Bank analyst Pito Chickering downgraded Baxter to Hold from Buy with a price target of $51, down from $69. The new price target assumes the shares trade at a 25% discount to the five year average, which is justified by the "bevy of macro headwinds" Baxter is facing, Chickering tells investors in a research note. The analyst is also in a pattern of continued guide downs and faces increased uncertainty around demand for capex-related products, particularly within the Hill-Rom portfolio, says the analyst.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAX:
- Baxter downgraded to Neutral from Buy at Citi
- Baxter sees some recessionary risk in 2023
- Shortages a Boon for These 2 Medical Device Stocks
- Rockwell Medical reacquires distribution rights to hemodialysis concentrates
- Baxter Highlights New Home Dialysis and HDx Therapy Data in 14 Clinical Presentations at Kidney Week 2022